{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T09:49:22Z","timestamp":1785750562073,"version":"3.56.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001259","name":"National Kidney Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ekir.2026.106618","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:13:29Z","timestamp":1780013609000},"page":"106618","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Target Trial of Glucagon-Like Peptide-1 Agonists versus Dipeptidyl Peptidase-4 Inhibitors and Mortality in Hemodialysis"],"prefix":"10.1016","volume":"11","author":[{"given":"Dustin","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kilpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter K.","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan E.","family":"Grams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard G.","family":"Jaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Im","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2026.106618_bib1","series-title":"2021 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States","year":"2021"},{"key":"10.1016\/j.ekir.2026.106618_bib2","article-title":"Prescribing trends of glucagon-like peptide 1 receptor agonists for type 2 diabetes or obesity","volume":"8","author":"Li","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ekir.2026.106618_bib3","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106618_bib4","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106618_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106618_bib6","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106618_bib7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106618_bib8","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO)","volume":"45","author":"Boer IH de","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2026.106618_bib9","doi-asserted-by":"crossref","first-page":"A8","DOI":"10.1053\/j.ajkd.2025.02.602","article-title":"US renal data system 2024 annual data report: epidemiology of kidney disease in the United States","volume":"85","author":"Johansen","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106618_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106618_bib11","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with Efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106618_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.1169","article-title":"Association of glucagon-like Peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease","volume":"5","author":"Chen","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ekir.2026.106618_bib13","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1053\/j.ajkd.2023.07.024","article-title":"Trial emulation methods","volume":"83","author":"Shin","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106618_bib14","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jama.2025.13350","article-title":"Transparent reporting of observational studies emulating a target trial\u2014the TARGET statement","volume":"334","author":"Cashin","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2026.106618_bib15","article-title":"GLP-1s versus DPP-4s and risk of dementia in patients requiring hemodialysis: a target trial emulation study","volume":"49","author":"Le","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2026.106618_bib16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/ki.2009.413","article-title":"An improved comorbidity index for outcome analyses among dialysis patients","volume":"77","author":"Liu","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106618_bib17","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like Peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ekir.2026.106618_bib18","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.kint.2023.11.025","article-title":"A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes","volume":"105","author":"Fu","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106618_bib19","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s12020-020-02223-6","article-title":"GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials","volume":"68","author":"Cao","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.ekir.2026.106618_bib20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ajo.2024.04.010","article-title":"Impact of GLP-1 agonists and SGLT-2 inhibitors on diabetic retinopathy progression: an aggregated electronic health record data study","volume":"265","author":"Wai","year":"2024","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ekir.2026.106618_bib21","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jclinepi.2013.01.013","article-title":"Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research","volume":"66","author":"Stuart","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ekir.2026.106618_bib22","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.ekir.2026.106618_bib23","series-title":"R: a Language and Environment for Statistical Computing","year":"2020"},{"key":"10.1016\/j.ekir.2026.106618_bib24","series-title":"Stata statistical software: release 17","year":"2021"},{"key":"10.1016\/j.ekir.2026.106618_bib25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2026.106618_bib26","author":"Bonamici"},{"key":"10.1016\/j.ekir.2026.106618_bib27","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.0006-341X.2000.00779.x","article-title":"Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests","volume":"56","author":"Robins","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.ekir.2026.106618_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102689","article-title":"Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study","volume":"73","author":"Tang","year":"2024","journal-title":"EClinicalmedicine"},{"key":"10.1016\/j.ekir.2026.106618_bib29","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/ndt\/gfs590","article-title":"Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial","volume":"28","author":"Iseki","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106618_bib30","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.ajkd.2008.04.031","article-title":"Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial","volume":"52","author":"Suzuki","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106618_bib31","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106618_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ekir.2026.106618_bib33","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.2215\/CJN.0000000750","article-title":"GLP-1 receptor agonist outcomes, safety, and BMI change in a national cohort of dialysis patients","volume":"20","author":"Orandi","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106618_bib34","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.0000001061","article-title":"Cardiovascular outcomes among new users of GLP-1 receptor agonists compared with DPP-4 inhibitors and sulfonylureas in kidney failure","author":"Catanese","year":"2026","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106618_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.13172","article-title":"GLP-1 Receptor agonist Discontinuation among patients with obesity and\/or type 2 diabetes","volume":"7","author":"Do","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ekir.2026.106618_bib36","doi-asserted-by":"crossref","first-page":"860","DOI":"10.18553\/jmcp.2024.23332","article-title":"Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes","volume":"30","author":"Gleason","year":"2024","journal-title":"JMCP"},{"key":"10.1016\/j.ekir.2026.106618_bib37","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1001\/jamacardio.2025.3109","article-title":"Discontinuation of semaglutide among older adults with diabetes in the US and Japan","volume":"10","author":"Inoue","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ekir.2026.106618_bib38","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2337\/dc24-1533","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials","volume":"48","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2026.106618_bib39","doi-asserted-by":"crossref","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"suppl_ 3","key":"10.1016\/j.ekir.2026.106618_bib40","doi-asserted-by":"crossref","first-page":"iii35","DOI":"10.1093\/ndt\/gfy175","article-title":"Chronic inflammation in end-stage renal disease and dialysis","volume":"33","author":"Cobo","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106618_bib41","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000520466","article-title":"Causes of death in end-stage kidney disease: comparison between the United States renal data system and a large integrated health care system","volume":"53","author":"Bhandari","year":"2022","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2026.106618_bib42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00592-020-01590-w","article-title":"Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes","volume":"58","author":"Ogundipe","year":"2021","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.ekir.2026.106618_bib43","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/ajcn\/81.3.543","article-title":"Survival advantages of obesity in dialysis patients","volume":"81","author":"Kalantar-Zadeh","year":"2005","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.ekir.2026.106618_bib44","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2026.106618_bib45","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.survophthal.2023.07.002","article-title":"GLP-1 receptor agonists and diabetic retinopathy: a meta-analysis of randomized clinical trials","volume":"68","author":"Kapoor","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ekir.2026.106618_bib46","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1681\/ASN.0000000693","article-title":"Glycemia assessed by continuous glucose monitoring among people treated with maintenance dialysis","volume":"36","author":"de Boer","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106618_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.00178","article-title":"GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials","volume":"11","author":"Gilbert","year":"2020","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ekir.2026.106618_bib50","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106618_bib51","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106618_bib52","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing semaglutide and liraglutide for alcohol use disorder","volume":"82","author":"L\u00e4hteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.ekir.2026.106618_bib53","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamapsychiatry.2025.0679","article-title":"Glucagon-like peptide 1 receptor agonists and mental health: a systematic review and meta-analysis","volume":"82","author":"Pierret","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.ekir.2026.106618_bib54","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ekir.2026.106618_bib55","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106618_bib56","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106618_bib57","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926028500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926028500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T09:34:10Z","timestamp":1785749650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024926028500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2468024926028500"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106618","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Target Trial of Glucagon-Like Peptide-1 Agonists versus Dipeptidyl Peptidase-4 Inhibitors and Mortality in Hemodialysis","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106618","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}],"article-number":"106618"}}